Thyroid carcinoma: molecular pathways and therapeutic targets
Top Cited Papers
Open Access
- 25 April 2008
- journal article
- review article
- Published by Elsevier in Laboratory Investigation
- Vol. 21 (2), S37-S43
- https://doi.org/10.1038/modpathol.2008.10
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Functional Characterization of the T1799-1801del and G1799-1816ins BRAF Mutations in Papillary Thyroid CancerCell Cycle, 2007
- New therapeutic approaches for metastatic thyroid carcinomaThe Lancet Oncology, 2007
- Targeting BRAF in thyroid cancerBritish Journal of Cancer, 2006
- Is BRAF the Achilles' Heel of Thyroid Cancer?Clinical Cancer Research, 2006
- The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membraneEndocrine-Related Cancer, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsOncogene, 2004
- The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibitionOncogene, 2004
- Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma: An Unusually High Prevalence of ras MutationsAmerican Journal of Clinical Pathology, 2003
- Molecular biology of the MEN2 geneJournal of Internal Medicine, 1998